Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023
February 28 2023 - 9:45AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron-mediated cell death, and immuno-oncology targeted novel
biologics, will be attending the 35th Annual ROTH Conference, being
held March 12–14 at The Ritz-Carlton Hotel in Dana Point,
California.
“We look forward to attending Roth this year and hosting
one-on-ones with members of the investment community. The small cap
ecosystem that Roth has created is an incredible opportunity to
share our investment thesis and showcase our therapeutic candidates
targeting drug resistant and devastating cancers,” says Randy
Milby, CEO of Hillstream.
The Company recently hosted its virtual R&D Day on February
14th, 2023 to discuss its preclinical study of its lead drug
candidate HSB-1216 along with other updates on its pipeline
candidates and Quatramer™ Tumor-Targeting platform.
To schedule a meeting with the management team at the 35th
Annual ROTH Conference, please send an email to
investorrelations@hillstreambio.com or visit
https://www.meetmax.com/sched/event_89809/conference_home.html.
About the 35th Annual Roth ConferenceThe 35th
Annual ROTH Conference, hosted by Roth MKM, will be held on March
12–14, 2023 and feature senior executives from approximately 500
private and public companies from a wide variety of sectors,
including AgTech, Consumer, Energy, Health & Wellness,
Healthcare, Industrial Growth, Metals and Mining, Sustainability,
Services, and Technology. The conference format comprises 1-on-1
and small group meetings, analyst-selected fireside chats, thematic
industry panels, on-demand presentations by companies that choose
to pre-record them, and live entertainment. For more information,
please visit:
https://www.meetmax.com/sched/event_89809/conference_home.html
About Hillstream BioPharma Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron mediated cell death, and immuno-oncology targeted novel
biologics. The Company’s most advanced candidate, HSB-1216,
preparing to potentially enter clinical trials in 2023, targets
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron mediated cell death (IMCD) of drug resistant cancers. The
Company’s emerging immuno-oncology pipeline is led by the HSB-1940
Quatrabody™, an anti-PD-1 novel biologic which could be coated onto
Quatramers, potentially enter the clinic in 2024. Hillstream’s
Quatramer™ proprietary tumor targeting platform extends duration of
action and minimizes off-target toxicity for biologics, mRNA,
peptides, small molecules and other modalities in the tumor
microenvironment. Quatrabody conjugates novel biologics developed
against undruggable epitopes of validated immuno-oncology targets,
including PD-1, HER2, PDL-1 and TROP2 with greater binding affinity
than approved therapies. For more information, please
visit: www.hillstreambio.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified using words such as “anticipate,” “believe,”
“forecast,” “estimated” and “intend” or other similar terms or
expressions that concern Hillstream’s expectations, strategy, plans
or intentions. These forward-looking statements are based on
Hillstream’s current expectations and actual results could differ
materially. There are several factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and
trials may not be predictive of future trial results; our clinical
trials may be suspended or discontinued due to unexpected side
effects or other safety risks that could preclude approval of our
product candidates; risks related to business interruptions,
including the outbreak of COVID-19 coronavirus, which could
seriously harm our financial condition and increase our costs and
expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2021 and our periodic reports filed
with the Securities and Exchange Commission. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as
of the date hereof, and Hillstream does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Investor Relations
ContactEmail: investorrelations@hillstreambio.comwww.hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2023 to Apr 2024